{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T17:55:37Z","timestamp":1648835737532},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2008,5,17]],"date-time":"2008-05-17T00:00:00Z","timestamp":1210982400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Z. Rheumatol."],"published-print":{"date-parts":[[2008,7]]},"DOI":"10.1007\/s00393-008-0297-2","type":"journal-article","created":{"date-parts":[[2008,5,15]],"date-time":"2008-05-15T09:41:02Z","timestamp":1210844462000},"page":"290-294","source":"Crossref","is-referenced-by-count":1,"title":["Progressive multifokale Leukoenzephalopathie bei rheumatologischen Erkrankungen"],"prefix":"10.1007","volume":"67","author":[{"given":"C.","family":"Kneitz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Wiendl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,5,17]]},"reference":[{"key":"297_CR1","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1056\/NEJMoa051586","volume":"353","author":"Van","year":"2005","unstructured":"Van Assche G, Van Ranst M, Sciot R et al. (2005) Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn\u2019s disease. N Engl J Med 353: 362\u2013368","journal-title":"N Engl J Med"},{"key":"297_CR2","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1002\/art.22657","volume":"56","author":"Calabrese","year":"2007","unstructured":"Calabrese HC, Molloy ES, Huang D, Ransohoff RM (2007) Progressive multifocal leukoencephalopathy in rheumatic diseases. Arthritis Rheum 56: 2116\u20132128","journal-title":"Arthritis Rheum"},{"key":"297_CR3","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1097\/00002030-199610090-00004","volume":"10","author":"Cinque","year":"1996","unstructured":"Cinque P, Vago L, Dahl H et al. (1996) Polymerase chain reaction on cerebrospinal fluid for diagnosis of virus-associated opportunistic diseases of the central nervous system in HIV-infected patients. AIDS 10: 951\u2013958","journal-title":"AIDS"},{"key":"297_CR4","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1212\/01.wnl.0000233918.21986.9c","volume":"67","author":"Eng","year":"2006","unstructured":"Eng PM, Turnbull BR, Cook SF et al. (2006) Characteristics and antecedents of progressive multifocal leukoencephalopathy in an insured population. Neurology 67: 884\u2013886","journal-title":"Neurology"},{"key":"297_CR5","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/art.22545","volume":"57","author":"Govindappa","year":"2007","unstructured":"Govindappa V, Hicks S, Wichter M, Jolly M (2007) Progressive multifocal leukoencephalopathy in systemic lupus erythematosus. Arthritis Rheum 57: 352\u2013354","journal-title":"Arthritis Rheum"},{"key":"297_CR6","first-page":"225","volume":"47","author":"Harris","year":"2008","unstructured":"Harris HE (2008) Progressive multifocal leukoencephalopathy in a patient with systemic lupus erythematosus treated with Rituximab. Rheumatology 47: 225\u2013226","journal-title":"Rheumatology"},{"key":"297_CR7","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1212\/WNL.58.12.1825","volume":"58","author":"Henderson","year":"2002","unstructured":"Henderson RD, Smith MG, Mowat P, Read SJ (2002) Progressive multifocal leukoencephalopathy. Neurology 58: 1825","journal-title":"Neurology"},{"key":"297_CR8","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1056\/NEJMoa051782","volume":"353","author":"Kleinschmidt-DeMasters","year":"2005","unstructured":"Kleinschmidt-DeMasters BK, Tyler KL (2005) Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 353: 369\u2013374","journal-title":"N Engl J Med"},{"key":"297_CR9","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1056\/NEJMoa051847","volume":"353","author":"Langer-Gould","year":"2005","unstructured":"Langer-Gould A, Atlas SW, Green AJ et al. (2005) Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Eng J Med 353: 375\u2013381","journal-title":"N Eng J Med"},{"key":"297_CR10","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/ana.20859","volume":"59","author":"Niino","year":"2006","unstructured":"Niino M, Bodner C, Simard ML et al. (2006) Natalizumab effects on immune cell responses in multiple sclerosis. Ann Neurol 59: 748\u2013754","journal-title":"Ann Neurol"},{"key":"297_CR11","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/S0140-6736(71)91777-6","volume":"1","author":"Padgett","year":"1971","unstructured":"Padgett BL, Walker DL, ZuRhein GM et al. (1971) Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. Lancet 1: 1257\u20131260","journal-title":"Lancet"},{"key":"297_CR12","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1093\/infdis\/127.4.467","volume":"127","author":"Padgett","year":"1973","unstructured":"Padgett BL, Walker DL (1973) Prevalence of antibodies in human sera against JC virus, an isolate from a case of progressive multifocal leukoencephalopathy. J Infect Dis 127: 467\u2013470","journal-title":"J Infect Dis"},{"key":"297_CR13","doi-asserted-by":"crossref","unstructured":"Du Pasquier RA, Koralnik IJ (2003) Inflammatory reaction in progressive multifocal leukoencephalopathy: harmful or beneficial? J Neurovirol (Suppl 1) 9: 25\u201331","DOI":"10.1080\/13550280390195315"},{"key":"297_CR14","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1038\/nn1005-1275","volume":"8","author":"Ransohoff","year":"2005","unstructured":"Ransohoff RM (2005) Natalizumab and PML. Nat Neurosci 8: 1275","journal-title":"Nat Neurosci"},{"key":"297_CR15","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/0002-9343(76)90383-1","volume":"61","author":"Rockwell","year":"1976","unstructured":"Rockwell D, Ruben FL, Winkelstein A, Mendelow H (1976) Absence of immune deficiencies in a case of progressive multifocal leukoencephalopathy. Am J Med 61: 433\u2013436","journal-title":"Am J Med"},{"key":"297_CR16","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa044396","volume":"354","author":"Rudick","year":"2006","unstructured":"Rudick RA, Stuart WH, Calabresi PA et al. (2006) Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Eng J Med 354: 911\u2013923","journal-title":"N Eng J Med"},{"key":"297_CR17","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1001\/archneur.64.2.169","volume":"64","author":"St\u00fcve","year":"2007","unstructured":"St\u00fcve O, Marra CM, Cravens PD et al. (2007) Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: possible interventions. Arch Neurol 64: 169\u2013176","journal-title":"Arch Neurol"},{"key":"297_CR18","unstructured":"US Food and Drug Administration (2006) FDA alert: rituximab (marketed as Rituxan). December 2006. http:\/\/www.fda.gov\/cder\/ drug\/InfoSheets\/HCP\/rituximab.pdf"},{"key":"297_CR19","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa054693","volume":"354","author":"Yousry","year":"2006","unstructured":"Yousry TA, Major EO, Ryschkewitsch C et al. (2006) Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 354: 924\u2013933","journal-title":"N Engl J Med"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-008-0297-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-008-0297-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-008-0297-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T16:35:56Z","timestamp":1559061356000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-008-0297-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5,17]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,7]]}},"alternative-id":["297"],"URL":"https:\/\/doi.org\/10.1007\/s00393-008-0297-2","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,5,17]]}}}